Modeling the clinical and economic implications of obesity using microsimulation

Abstract

This validated model helps illustrate why obese adults have higher medical and indirect costs relative to normal weight adults, and shows that medical costs for obese adults rise more rapidly with aging relative to normal weight adults.

Adolescent Snacking Behaviors Are Associated with Dietary Intake and Weight Status

“…Model estimates were also adjusted for total weekly hours of television viewing. 3 Model estimates were also adjusted for total energy intake. 2 Model estimates were also adjusted for continuous underreporting on the basis of the ratio of energy intake to estimated energy requirement.…”

“…2 Model estimates were also adjusted for continuous underreporting on the basis of the ratio of energy intake to estimated energy requirement. 3 Response options were assigned scores of scores of 5 = always, 4 = usually, 3 = sometimes, 2 = rarely, and 1 = never. Model estimates were also adjusted for total weekly hours of television viewing.…”

“…Poor dietary habits and weight-related problems have serious consequences for the health of young people in the United States and take a heavy economic toll on the nation (1)(2)(3). Because the foods and beverages consumed at snack occasions account for a large proportion of adolescentsÕ overall diets (4), snacking behaviors are important to consider as a component of dietary counseling and public health strategies targeting these problems.…”

Economic Burden of Obesity: A Systematic Literature Review

“…Since 2011, however, advanced methods such as microsimulation modelling [29,30,31] have been used and have led to new findings, requiring further, systematic exploration. Furthermore, some reviews have included studies that were specific to a single country or continent, e.g., the USA [18,26], Canada [24] or Europe [21,22,27], and have excluded studies from all over the world.…”

A new angle for glp-1 receptor agonist: the medical economics argument

“…Diabetes imposes a large economic burden that will continue to increase in the next two decades, especially in older adults, because of a higher prevalence of diabetes and higher rates of diabetes-related complications in older age-groups 17 . Obesity also imposes higher costs in adults, negatively impacting income and quality-of-life 18 . Compared with metformin and sulfonylureas, newer agents have substantially higher drug acquisition costs, with DPP-4 inhibitors being less expensive than GLP-1 receptor agonists.…”